首页 > 最新文献

Medical Journal of Australia最新文献

英文 中文
Interval Cancer Characteristics, Staging and Survival Among National Bowel Cancer Screening Program Participants, Western Australia, 2018: A Retrospective Observational Cohort Study 2018年西澳大利亚国家肠癌筛查项目参与者的间隔期癌症特征、分期和生存:一项回顾性观察性队列研究。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-02-02 DOI: 10.5694/mja2.70138
Shantelle J. Smith, Rachael Moorin, Dagmawi Tadesse, Kathleen O'Connor, Thi Ninh Ha
<div> <section> <h3> Objective</h3> <p>To examine the features of interval colorectal cancer (interval CRC) in Western Australia in the context of the National Bowel Cancer Screening Program (NBCSP), including incidence, characteristics and survival by NBCSP participant characteristics.</p> </section> <section> <h3> Study Design</h3> <p>Retrospective observational cohort study, analysis of linked National Cancer Screening Register and Western Australian Cancer Registry data.</p> </section> <section> <h3> Participants, Setting</h3> <p>Participants in the Western Australian NBCSP (50–74 years of age) with negative immunochemical faecal occult blood test (iFOBT) results during the 2018 screening round (1 January 2018–31 December 2018) were followed up for interval CRC diagnoses until 31 December 2020, and for death until 30 September 2022.</p> </section> <section> <h3> Main Outcome Measures</h3> <p>Crude and adjusted incidence rates of interval CRC were analysed overall and by sex, age group and residential socio-economic and remoteness categories. Survival outcomes for people with interval CRC were also assessed.</p> </section> <section> <h3> Results</h3> <p>Of 122,851 NBCSP participants with negative screening results in 2018, 51 people were diagnosed with interval CRC during follow-up (crude incidence rate, 21 per 100,000 person-years; 95% confidence interval [CI], 16–27). The adjusted incidence rate ratio of interval CRC was higher for men than women (adjusted incidence rate ratio [aIRR], 5; 95% CI, 3–11) and for people aged 70–74 years than for those aged 50–59 years (aIRR, 3; 95% CI, 1–6). Nineteen of 51 interval CRCs were diagnosed 19–24 months after negative iFOBT results, 25 were located on the right side of the colon and 34 were adenocarcinomas. Only 13 interval CRCs were stage I tumours at diagnosis. During follow-up (median, 33 months; interquartile range, 28–42 months), the all-cause mortality rate among the 51 people with interval CRC was 41 per 1000 person-years (95% CI, 18–92), and the colorectal cancer mortality rate was 35 per 1000 person-years (95% CI, 14–83).</p> </section> <section> <h3> Conclusions</h3> <p>We provide a comprehensive analysis of interval CRC staging and clinical characteristics in the context of the NBCSP in Western Australia, facilitating the definition of benchmarks for monitoring programme performance.</p>
目的:探讨在国家肠癌筛查计划(NBCSP)的背景下,西澳大利亚州间期结直肠癌(interval CRC)的特征,包括NBCSP参与者的发病率、特征和生存率。研究设计:回顾性观察队列研究,分析相关的国家癌症筛查登记和西澳大利亚癌症登记数据。参与者,环境:在2018年筛查轮(2018年1月1日至2018年12月31日)期间,西澳大利亚州NBCSP(50-74岁)中免疫化学粪便隐血试验(iFOBT)结果阴性的参与者随访至2020年12月31日,随访至2022年9月30日,随访至间隔CRC诊断。主要结果测量:对粗发病率和调整后的间隔期结直肠癌发病率进行总体分析,并按性别、年龄组、居住社会经济和偏远地区类别进行分析。间隔期结直肠癌患者的生存结果也被评估。结果:在2018年筛查结果为阴性的122,851名NBCSP参与者中,51人在随访期间被诊断为间期结直肠癌(粗发病率为21 / 100,000人-年;95%置信区间[CI], 16-27)。男性间期结直肠癌的调整发病率比高于女性(调整发病率比[aIRR], 5; 95% CI, 3-11), 70-74岁人群的调整发病率比高于50-59岁人群(aIRR, 3; 95% CI, 1-6)。51例间期crc中有19例在iFOBT阴性后19-24个月被诊断出来,其中25例位于结肠右侧,34例为腺癌。只有13例间期crc在诊断时为I期肿瘤。在随访期间(中位33个月;四分位数范围28-42个月),51例间隔期结直肠癌患者的全因死亡率为每1000人年41例(95% CI, 18-92),结直肠癌死亡率为每1000人年35例(95% CI, 14-83)。结论:我们在西澳大利亚州NBCSP的背景下,对间隔期CRC分期和临床特征进行了全面分析,促进了监测项目绩效基准的定义。
{"title":"Interval Cancer Characteristics, Staging and Survival Among National Bowel Cancer Screening Program Participants, Western Australia, 2018: A Retrospective Observational Cohort Study","authors":"Shantelle J. Smith,&nbsp;Rachael Moorin,&nbsp;Dagmawi Tadesse,&nbsp;Kathleen O'Connor,&nbsp;Thi Ninh Ha","doi":"10.5694/mja2.70138","DOIUrl":"10.5694/mja2.70138","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To examine the features of interval colorectal cancer (interval CRC) in Western Australia in the context of the National Bowel Cancer Screening Program (NBCSP), including incidence, characteristics and survival by NBCSP participant characteristics.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Study Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Retrospective observational cohort study, analysis of linked National Cancer Screening Register and Western Australian Cancer Registry data.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Participants, Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Participants in the Western Australian NBCSP (50–74 years of age) with negative immunochemical faecal occult blood test (iFOBT) results during the 2018 screening round (1 January 2018–31 December 2018) were followed up for interval CRC diagnoses until 31 December 2020, and for death until 30 September 2022.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main Outcome Measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Crude and adjusted incidence rates of interval CRC were analysed overall and by sex, age group and residential socio-economic and remoteness categories. Survival outcomes for people with interval CRC were also assessed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Of 122,851 NBCSP participants with negative screening results in 2018, 51 people were diagnosed with interval CRC during follow-up (crude incidence rate, 21 per 100,000 person-years; 95% confidence interval [CI], 16–27). The adjusted incidence rate ratio of interval CRC was higher for men than women (adjusted incidence rate ratio [aIRR], 5; 95% CI, 3–11) and for people aged 70–74 years than for those aged 50–59 years (aIRR, 3; 95% CI, 1–6). Nineteen of 51 interval CRCs were diagnosed 19–24 months after negative iFOBT results, 25 were located on the right side of the colon and 34 were adenocarcinomas. Only 13 interval CRCs were stage I tumours at diagnosis. During follow-up (median, 33 months; interquartile range, 28–42 months), the all-cause mortality rate among the 51 people with interval CRC was 41 per 1000 person-years (95% CI, 18–92), and the colorectal cancer mortality rate was 35 per 1000 person-years (95% CI, 14–83).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We provide a comprehensive analysis of interval CRC staging and clinical characteristics in the context of the NBCSP in Western Australia, facilitating the definition of benchmarks for monitoring programme performance.&lt;/p&gt;\u0000 ","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 2","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.70138","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146106119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategies for Reducing Access Block and Waiting Time for Patients Seeking Emergency Hospital Care: Results of a Ward-Level Discrete Event Simulation at Queensland's Largest Public Hospitals. 减少就诊阻塞和患者寻求紧急医院护理等待时间的策略:昆士兰州最大的公立医院病房级离散事件模拟的结果。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-02-01 DOI: 10.5694/mja2.70142
Hamed Hassanzadeh, Justin Boyle, Vahid Riahi, Hwan-Jin Yoon, Ibrahima Diouf, Sankalp Khanna, Clair Sullivan, Andrew Staib, Emma Bosley, Mahnaz Samadbeik, James F Lind

Objective: To assess the impact of strategies to improve public hospital emergency access using a detailed ward-level simulation modelling approach.

Design and setting: Discrete event simulation was used to simulate patient flow at three principal referral Australian hospitals from 1 September 2021 to 31 August 2022. Models were developed and validated using every emergency department (ED) presentation, inpatient episode of care and patient ward movement at the study hospitals.

Main outcome measures: Mean and total ED length of stay, mean waiting time, access block rate, 4-h rule compliance and bed utilisation for patients admitted from the ED.

Results: Reducing ED demand via arrangements that accommodate the same proportion and types of admissions from the ED as the existing ED presenting population reduces access block, with larger impacts in winter than in summer. However, reducing 'general practitioner-type patients' in EDs has negligible impact on access block. Tangible impacts on improving patient flow can be achieved by removing maintenance care patients from hospitals (reducing the percentage of access block by up to a third) and reducing elective admissions. Strategies that emphasised morning, midday and early afternoon discharges led to large flow improvements. The strategy already practised by most hospitals of sharing patients among wards greatly improves emergency access, and gains are the same order of magnitude as reducing overall ED demand.

Conclusions: The study provides support to policymakers looking for evidence regarding strategies to improve emergency access to public hospital care.

目的:采用详细的病房级模拟建模方法,评估改善公立医院急诊通道的策略的影响。设计和环境:离散事件模拟用于模拟2021年9月1日至2022年8月31日期间澳大利亚三家主要转诊医院的患者流量。模型的开发和验证使用每个急诊科(ED)的表现,住院病人的护理事件和病人的病房移动在研究医院。主要结果测量:平均和总住院时间、平均等待时间、就诊阻塞率、4小时规则依从性和从急诊科入院的患者的床位利用率。结果:通过安排适应与现有急诊科就诊人口相同的比例和类型的急诊科入院,减少急诊科的需求,减少就诊阻塞,冬季的影响比夏季更大。然而,减少“全科医生型患者”在急诊科的影响可以忽略不计。通过将维持性护理患者从医院中移除(最多减少三分之一的访问阻塞百分比)和减少选择性住院,可以对改善患者流动产生切实影响。强调早上,中午和下午早些时候的策略导致流量的大幅改善。大多数医院已经实行的在不同病房共享病人的策略大大改善了急诊通道,其收益与减少急诊科的总体需求是相同的。结论:本研究为政策制定者寻找改善急诊获得公立医院护理的策略证据提供了支持。
{"title":"Strategies for Reducing Access Block and Waiting Time for Patients Seeking Emergency Hospital Care: Results of a Ward-Level Discrete Event Simulation at Queensland's Largest Public Hospitals.","authors":"Hamed Hassanzadeh, Justin Boyle, Vahid Riahi, Hwan-Jin Yoon, Ibrahima Diouf, Sankalp Khanna, Clair Sullivan, Andrew Staib, Emma Bosley, Mahnaz Samadbeik, James F Lind","doi":"10.5694/mja2.70142","DOIUrl":"10.5694/mja2.70142","url":null,"abstract":"<p><strong>Objective: </strong>To assess the impact of strategies to improve public hospital emergency access using a detailed ward-level simulation modelling approach.</p><p><strong>Design and setting: </strong>Discrete event simulation was used to simulate patient flow at three principal referral Australian hospitals from 1 September 2021 to 31 August 2022. Models were developed and validated using every emergency department (ED) presentation, inpatient episode of care and patient ward movement at the study hospitals.</p><p><strong>Main outcome measures: </strong>Mean and total ED length of stay, mean waiting time, access block rate, 4-h rule compliance and bed utilisation for patients admitted from the ED.</p><p><strong>Results: </strong>Reducing ED demand via arrangements that accommodate the same proportion and types of admissions from the ED as the existing ED presenting population reduces access block, with larger impacts in winter than in summer. However, reducing 'general practitioner-type patients' in EDs has negligible impact on access block. Tangible impacts on improving patient flow can be achieved by removing maintenance care patients from hospitals (reducing the percentage of access block by up to a third) and reducing elective admissions. Strategies that emphasised morning, midday and early afternoon discharges led to large flow improvements. The strategy already practised by most hospitals of sharing patients among wards greatly improves emergency access, and gains are the same order of magnitude as reducing overall ED demand.</p><p><strong>Conclusions: </strong>The study provides support to policymakers looking for evidence regarding strategies to improve emergency access to public hospital care.</p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 2","pages":"e70142"},"PeriodicalIF":8.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12946774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147307379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of Hospital Bed Occupancy on Patient Flow and Emergency Department Access: A 25-Hospital Cohort Study. 医院床位占用率对病人流量和急诊科准入的影响:一项25家医院队列研究。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-02-01 DOI: 10.5694/mja2.70143
Vahid Riahi, Justin Boyle, Hwan-Jin Yoon, Hamed Hassanzadeh, Ibrahima Diouf, Sankalp Khanna, Andrew Staib, Mahnaz Samadbeik, Clair Sullivan, Emma Bosley, James F Lind

Objectives: To evaluate the effect of hospital occupancy levels on inpatient and emergency department (ED) flow rates, ED length of stay (ED) and access block, and identify critical occupancy thresholds above which patient flow deteriorates.

Design: Retrospective cohort study using routinely collected administrative data.

Setting: Twenty-five public hospitals in Queensland, Australia, over a 5.5-year period (1 April 2017 to 31 August 2022).

Main outcome measures: ED presentation and discharge rates, inpatient admission and discharge rates, hospital occupancy levels, length of stay, access block and 4-h rule compliance.

Results: The analysis reveals a significant performance shift as hospital occupancy levels increase and identifies site-specific critical 'choke points' where patient flow deteriorates. Notably, as occupancy rises, we observed a growing divergence between ED presentations and discharge rates, and between inpatient admissions and discharges, indicating system congestion. Additionally, when assessing flow across the 25 hospitals, the data demonstrates that a 10% increase in bed occupancy rate correlates with a 0.32-h (19-min) extension in ED length of stay (or 33 min for patients admitted from the ED). Also, significant disparities in hospital operations were observed between weekends and weekdays, with weekday admissions and discharges up to three times higher than weekends, highlighting the increased operational pressure during the work week.

Conclusions: The investigation challenges the traditional 85% occupancy target, demonstrating that optimal occupancy levels vary by hospital. The study also underscores the strong correlation between hospital bed occupancy and ED access performance, with higher hospital occupancy correlating with longer ED stays and decreased adherence to performance indicators. As hospitals approach full capacity, the pressure on ED resources intensifies, resulting in longer wait times and delays in care.

目的:评价医院占用率对急诊科(ED)流量、ED住院时间(ED)和通道阻塞的影响,并确定超过患者流量恶化的临界占用阈值。设计:回顾性队列研究,使用常规收集的行政资料。环境:在5.5年期间(2017年4月1日至2022年8月31日),澳大利亚昆士兰州的25家公立医院。主要结局指标:急症表现和出院率、住院和出院率、医院入住率、住院时间、通道阻塞和4小时规则遵守情况。结果:分析揭示了随着医院入住率的增加,显著的性能变化,并确定了特定地点的关键“阻塞点”,患者流量恶化。值得注意的是,随着入住率的增加,我们观察到急诊科报告和出院率之间以及住院和出院之间的差异越来越大,这表明系统拥挤。此外,在评估25家医院的流量时,数据表明,10%的床位占用率增加与急诊室住院时间延长0.32小时(19分钟)相关(或从急诊室入院的患者延长33分钟)。此外,在周末和工作日之间观察到医院手术的巨大差异,工作日的入院和出院人数比周末高出三倍,突出表明在工作周期间的业务压力增加。结论:调查挑战了传统的85%的入住率目标,表明最佳入住率水平因医院而异。该研究还强调了医院床位占用率与急诊科使用绩效之间的强相关性,较高的医院占用率与较长的急诊科停留时间和较低的绩效指标依从性相关。随着医院接近满负荷,急诊科资源的压力加剧,导致等待时间延长和护理延误。
{"title":"The Impact of Hospital Bed Occupancy on Patient Flow and Emergency Department Access: A 25-Hospital Cohort Study.","authors":"Vahid Riahi, Justin Boyle, Hwan-Jin Yoon, Hamed Hassanzadeh, Ibrahima Diouf, Sankalp Khanna, Andrew Staib, Mahnaz Samadbeik, Clair Sullivan, Emma Bosley, James F Lind","doi":"10.5694/mja2.70143","DOIUrl":"10.5694/mja2.70143","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the effect of hospital occupancy levels on inpatient and emergency department (ED) flow rates, ED length of stay (ED) and access block, and identify critical occupancy thresholds above which patient flow deteriorates.</p><p><strong>Design: </strong>Retrospective cohort study using routinely collected administrative data.</p><p><strong>Setting: </strong>Twenty-five public hospitals in Queensland, Australia, over a 5.5-year period (1 April 2017 to 31 August 2022).</p><p><strong>Main outcome measures: </strong>ED presentation and discharge rates, inpatient admission and discharge rates, hospital occupancy levels, length of stay, access block and 4-h rule compliance.</p><p><strong>Results: </strong>The analysis reveals a significant performance shift as hospital occupancy levels increase and identifies site-specific critical 'choke points' where patient flow deteriorates. Notably, as occupancy rises, we observed a growing divergence between ED presentations and discharge rates, and between inpatient admissions and discharges, indicating system congestion. Additionally, when assessing flow across the 25 hospitals, the data demonstrates that a 10% increase in bed occupancy rate correlates with a 0.32-h (19-min) extension in ED length of stay (or 33 min for patients admitted from the ED). Also, significant disparities in hospital operations were observed between weekends and weekdays, with weekday admissions and discharges up to three times higher than weekends, highlighting the increased operational pressure during the work week.</p><p><strong>Conclusions: </strong>The investigation challenges the traditional 85% occupancy target, demonstrating that optimal occupancy levels vary by hospital. The study also underscores the strong correlation between hospital bed occupancy and ED access performance, with higher hospital occupancy correlating with longer ED stays and decreased adherence to performance indicators. As hospitals approach full capacity, the pressure on ED resources intensifies, resulting in longer wait times and delays in care.</p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 2","pages":"e70143"},"PeriodicalIF":8.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12946772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147307331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations Between Hospital Occupancy, Emergency Department Function and Ambulance Delays, With Modelled Mitigation Strategies: Evidence From Acute Queensland Hospitals. 医院占用率、急诊科功能和救护车延误之间的关联,以及模拟缓解策略:来自昆士兰州急性医院的证据。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-02-01 DOI: 10.5694/mja2.70148
David Mountain

This editorial highlights three studies that collectively offer a roadmap towards system-level improvement in access, flow and quality of care. These studies used linked data from several Queensland hospitals and explored emergency department (ED)-hospital capacity associations with ambulance, ED and hospital dysfunction. One study found ED occupancy was strongly associated with ambulance dysfunction (ramping, response times). The second study associated hospital occupancy with ED dysfunction. Larger hospitals with occupancies above 85%-90% became dysregulated with rapid overcrowding. The modelling study in three tertiary hospitals reported that reduced admissions (ED or elective procedures), improved discharges (earlier, quicker community discharge, home care) and flexible bed use (any ward, over-census) improved flow. Diverting general practice-type attendances and weekend surgery seemed ineffective. Rapid, adequate flexible admitting capacity seems important for safe, efficient hospital-ED care and ambulance function.

这篇社论强调了三项研究,它们共同提供了在获得、流动和质量方面改善系统级护理的路线图。这些研究使用了昆士兰几家医院的相关数据,并探讨了急诊室(ED)-医院容量与救护车、ED和医院功能障碍的关系。一项研究发现急诊科占用率与救护车功能障碍(斜坡,反应时间)密切相关。第二项研究将住院率与ED功能障碍联系起来。入住率在85%-90%以上的大型医院由于过度拥挤而变得不规范。在三所三级医院进行的模拟研究报告说,减少住院人数(急诊科或选择性手术)、改善出院(更早、更快地社区出院、家庭护理)和灵活的床位使用(任何病房、过度普查)改善了流量。转移全科医生的出勤和周末手术似乎是无效的。快速、充足的灵活收治能力对于安全、高效的医院急诊科护理和救护车功能似乎很重要。
{"title":"Associations Between Hospital Occupancy, Emergency Department Function and Ambulance Delays, With Modelled Mitigation Strategies: Evidence From Acute Queensland Hospitals.","authors":"David Mountain","doi":"10.5694/mja2.70148","DOIUrl":"https://doi.org/10.5694/mja2.70148","url":null,"abstract":"<p><p>This editorial highlights three studies that collectively offer a roadmap towards system-level improvement in access, flow and quality of care. These studies used linked data from several Queensland hospitals and explored emergency department (ED)-hospital capacity associations with ambulance, ED and hospital dysfunction. One study found ED occupancy was strongly associated with ambulance dysfunction (ramping, response times). The second study associated hospital occupancy with ED dysfunction. Larger hospitals with occupancies above 85%-90% became dysregulated with rapid overcrowding. The modelling study in three tertiary hospitals reported that reduced admissions (ED or elective procedures), improved discharges (earlier, quicker community discharge, home care) and flexible bed use (any ward, over-census) improved flow. Diverting general practice-type attendances and weekend surgery seemed ineffective. Rapid, adequate flexible admitting capacity seems important for safe, efficient hospital-ED care and ambulance function.</p>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 2","pages":"e70148"},"PeriodicalIF":8.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147307367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MJA in 2026: New Processes and a New Look 2026年的MJA:新工艺和新面貌。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-26 DOI: 10.5694/mja2.70139
Virginia Barbour
<p>2026 marks an inflection point for the <i>MJA</i> in a number of ways. During 2025, we spent time considering how best to position the journal for the future.</p><p>Some of this work relates to how the journal will look, and some of this relates to how we will manage our processes going forward. In doing this work, we had to balance several priorities, keeping in mind our primary purpose to publish high-quality research and commentary that will inform health policy and influence medical practice in Australia. Like all journals, our priorities and values are not neutral but are set by the editorial team: journals are a human endeavour.</p><p>Our challenge, as for all journals, is to balance our capacities with our values and priorities in order to produce a journal that week by week publishes a diverse range of content that will be of interest to as wide a range of practitioners, researchers and policymakers as possible across the Australian health system.</p><p>We recognise that in our role as journal editors, we have a great deal of power over what gets published, and we also know that because of that, what we do directly impacts the lives and careers of authors. We aim therefore to provide authors with a constructive, collaborative process during peer review and publication. Even for papers that we do not send for review, we aim to be as fast as possible in our decision-making and, where we can, to provide feedback.</p><p>But the mathematics of journals can make it hard to balance speed with detailed processes.</p><p>In the 3 years that I have been Editor-in-Chief, submissions have risen from 1413 in 2023 to 1619 in 2025. Submissions from Australia have increased slightly—from 1020 to 1087. Submissions from the rest of the world have risen from 393 to 532 and now represent almost 33% of submissions. The overall challenge that we face, along with all journals that have to be selective in what they publish, is that in order to publish high-quality papers, we need to focus on papers that closely fit our scope and spend as little time as possible on papers that we will not publish.</p><p>In my experience, the papers we receive largely fall into one of four groups, as follows.</p><p>The first group is those we would never publish regardless of their quality, as they simply do not report on an issue that we can see has relevance to Australian health care, either because of the non-Australian study population or setting, health topic, or because they are too pre-clinical. Some of these papers now bear obvious hallmarks of being the product of paper mills. I would urge authors whose papers fit into this category to consider carefully the value of submitting their papers to the <i>MJA</i>. We will never publish them, and processing these papers takes up the finite time of editors and authors.</p><p>The second group is of papers that may have relevance to an aspect of Australian health care but do not fit in our qualitative criteria as a high priority
2026年在很多方面都标志着MJA的一个转折点。在2025年,我们花时间考虑如何最好地定位杂志的未来。其中一些工作与期刊的外观有关,还有一些与我们如何管理我们的流程有关。在做这项工作时,我们必须平衡几个优先事项,牢记我们的主要目的是发表高质量的研究和评论,这些研究和评论将为澳大利亚的卫生政策提供信息并影响医疗实践。像所有期刊一样,我们的优先事项和价值观不是中立的,而是由编辑团队设定的:期刊是一项人类的努力。与所有期刊一样,我们面临的挑战是平衡我们的能力与我们的价值观和优先事项,以便每周出版一本能够让澳大利亚卫生系统中尽可能广泛的从业人员、研究人员和政策制定者感兴趣的内容多样化的期刊。我们认识到,作为期刊编辑,我们对发表的内容有很大的决定权,我们也知道,正因为如此,我们所做的事情直接影响到作者的生活和事业。因此,我们的目标是在同行评审和出版过程中为作者提供一个建设性的合作过程。即使是我们没有送去审稿的论文,我们的目标也是尽可能快地做出决策,并在可能的情况下提供反馈。但是,期刊的数学运算会让你很难在速度和细节过程之间取得平衡。在我担任主编的3年里,投稿量从2023年的1413篇上升到2025年的1619篇。来自澳大利亚的申请略有增加,从1020份增加到1087份。来自世界其他地区的申请从393份增加到532份,现在几乎占所有申请的33%。我们所面临的总体挑战,以及所有期刊必须有选择性地发表的内容,是为了发表高质量的论文,我们需要关注那些与我们的研究范围密切相关的论文,并尽可能少地花时间在那些我们不会发表的论文上。根据我的经验,我们收到的论文主要分为以下四类。第一组是那些无论其质量如何我们都不会发表的,因为他们根本没有报告我们认为与澳大利亚医疗保健相关的问题,要么是因为非澳大利亚的研究人群或环境,健康主题,要么是因为他们过于临床前。其中一些纸现在带有造纸厂产品的明显标志。我强烈建议论文属于这一类的作者仔细考虑向MJA提交论文的价值。我们永远不会发表这些论文,处理这些论文占用了编辑和作者有限的时间。第二组是可能与澳大利亚卫生保健的某个方面相关但不符合我们作为高度优先事项的定性标准的论文。这些标准在我们的作者和审稿人指南中进行了概述,可以总结如下:与澳大利亚的高疾病负担有关;具有高度公共卫生利益的;原住民和托雷斯海峡岛民主导的研究或评论;或可能对澳大利亚的临床实践或政策产生直接影响的主题。第三种是符合我们的定性标准的论文,但在设计或写作上有一些东西告诉我们,存在一个作者无法解决的基本问题,或者需要期刊的过多投入来解决。其中一些问题可能包括评估研究可能缺乏严谨性或产生难以解释的发现,因为不适当的设计或分析、伦理或治理问题、不良报告(例如,没有使用报告指南)或缺乏对基础数据的访问。对于非研究稿件,一个常见的限制是它们没有很好地建立在以前的工作基础上。不用说,这组论文可能是最难评估的。最后,有些论文确实符合我们的标准,并且在最初的阅读中,报道或写作都很好,并且编辑团队没有发现明显的问题,因此无法发表。这些是我们发给同行评审的论文,如果没有发现实质性问题,我们将最终发表。这一切与我们在2025年所做的战略工作有什么关系?从本质上讲,了解我们需要如何工作是计划如何有效地管理期刊流程的关键。第一个变化是我们重组了我们的团队。从2026年开始,MJA内部决定稿件的团队由总编辑、副编辑、两名高级编辑和五名兼职副编辑组成,他们除了外部临床或学术工作外,每周还将为我们工作一天。 通过招募这些副编辑,我们打算将我们的影响力扩大到澳大利亚的研究和卫生保健社区,同时,在编辑过程中建立能力。我们的目的是,多年来,我们将建立一个庞大的临床医生和医学学者队伍,他们也将有编辑的经验。因此,我们将做出的一个改变是,我们将更有选择性地将哪些论文发送给外部同行评审。我们希望这将引起那些我们要求审查的人的共鸣。我们认识到审稿人的时间是宝贵的,我们知道尽管有局限性,同行评议确实为作者提供了重要的反馈。我们认识到审稿人是MJA社区的重要组成部分,我们希望通过向审稿人发送更少的论文,他们将能够更好地支持他们所做的审稿工作。对于那些未经同行评议而被我们拒绝的论文,我们打算迅速做出决定。我们还对审查后和接受前后处理论文的流程进行了更改。再一次,我们重组了我们的团队,包括一个管理编辑和一个出版项目编辑。虽然我们将继续编辑论文以检查错别字或明显的不一致,但我们不会在接受后对论文进行大规模的重组或结构性编辑。我们要做的是与作者进行更密切的预接受合作,所以一旦论文被接受,之后就只需要进行最小的修改。实际上,对于作者来说,这将意味着,论文一旦被接受,将比以前更快地出现在网上。最后,我们将对个别期刊文章和期刊的整体外观以及出版节奏做出改变。这种变化已经开始于一种新的PDF格式——首先在这里看到:https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.70115。从2026年第1期开始,文章不再与特定的时间挂钩,而是连续出版,并从每年22次开始改为每月末出版。此外,在2026年年中,我们的网站将进行彻底的重新设计,以更好地展示和功能。所有这些变化都是经过精心策划的,我们希望对作者和读者来说,所看到的唯一影响是积极的,但是,一如既往,我们欢迎反馈。我们共同期待通过我们的出版继续我们的使命,提供高质量的证据和见解,以支持澳大利亚卫生保健和卫生公平的进步。
{"title":"MJA in 2026: New Processes and a New Look","authors":"Virginia Barbour","doi":"10.5694/mja2.70139","DOIUrl":"10.5694/mja2.70139","url":null,"abstract":"&lt;p&gt;2026 marks an inflection point for the &lt;i&gt;MJA&lt;/i&gt; in a number of ways. During 2025, we spent time considering how best to position the journal for the future.&lt;/p&gt;&lt;p&gt;Some of this work relates to how the journal will look, and some of this relates to how we will manage our processes going forward. In doing this work, we had to balance several priorities, keeping in mind our primary purpose to publish high-quality research and commentary that will inform health policy and influence medical practice in Australia. Like all journals, our priorities and values are not neutral but are set by the editorial team: journals are a human endeavour.&lt;/p&gt;&lt;p&gt;Our challenge, as for all journals, is to balance our capacities with our values and priorities in order to produce a journal that week by week publishes a diverse range of content that will be of interest to as wide a range of practitioners, researchers and policymakers as possible across the Australian health system.&lt;/p&gt;&lt;p&gt;We recognise that in our role as journal editors, we have a great deal of power over what gets published, and we also know that because of that, what we do directly impacts the lives and careers of authors. We aim therefore to provide authors with a constructive, collaborative process during peer review and publication. Even for papers that we do not send for review, we aim to be as fast as possible in our decision-making and, where we can, to provide feedback.&lt;/p&gt;&lt;p&gt;But the mathematics of journals can make it hard to balance speed with detailed processes.&lt;/p&gt;&lt;p&gt;In the 3 years that I have been Editor-in-Chief, submissions have risen from 1413 in 2023 to 1619 in 2025. Submissions from Australia have increased slightly—from 1020 to 1087. Submissions from the rest of the world have risen from 393 to 532 and now represent almost 33% of submissions. The overall challenge that we face, along with all journals that have to be selective in what they publish, is that in order to publish high-quality papers, we need to focus on papers that closely fit our scope and spend as little time as possible on papers that we will not publish.&lt;/p&gt;&lt;p&gt;In my experience, the papers we receive largely fall into one of four groups, as follows.&lt;/p&gt;&lt;p&gt;The first group is those we would never publish regardless of their quality, as they simply do not report on an issue that we can see has relevance to Australian health care, either because of the non-Australian study population or setting, health topic, or because they are too pre-clinical. Some of these papers now bear obvious hallmarks of being the product of paper mills. I would urge authors whose papers fit into this category to consider carefully the value of submitting their papers to the &lt;i&gt;MJA&lt;/i&gt;. We will never publish them, and processing these papers takes up the finite time of editors and authors.&lt;/p&gt;&lt;p&gt;The second group is of papers that may have relevance to an aspect of Australian health care but do not fit in our qualitative criteria as a high priority","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.70139","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146052710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valproate Prescribing for Female Adolescents and Management of the Associated Teratogenicity Risk, Royal Children's Hospital, Melbourne, 2022–2024: A Retrospective Audit of Medical Records Data 女性青少年丙戊酸处方及相关致畸风险的管理,墨尔本皇家儿童医院,2022-2024:对医疗记录数据的回顾性审计。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-21 DOI: 10.5694/mja2.70126
Briana Davis, Monica S. Cooper, Michael South, Jeremy L. Freeman, Emma Macdonald-Laurs
<div> <section> <h3> Objectives</h3> <p>To assess the frequency of valproate prescribing for female patients of childbearing age at the Royal Children's Hospital, Melbourne, and to assess the frequency of documented discussions with these patients about the teratogenicity of valproate and the discussions or prescribing of contraception.</p> </section> <section> <h3> Study Design</h3> <p>Retrospective audit of hospital electronic medical records data; analysis of Pharmaceutical Benefits Scheme (PBS) valproate dispensing data.</p> </section> <section> <h3> Setting, Participants</h3> <p>13- to 18-year-old girls or women prescribed valproate at the Royal Children's Hospital, Melbourne during 29 May 2022–29 May 2024; PBS valproate dispensing data for Australia for the 2023 calendar year.</p> </section> <section> <h3> Main Outcome Measures</h3> <p>Characteristics of adolescent female patients prescribed valproate; documented discussions of valproate-related teratogenicity, and discussions or prescribing of contraception; population valproate prescribing rates for Australia and by state.</p> </section> <section> <h3> Results</h3> <p>Valproate was prescribed for 245 female patients aged 13–18 years during 2022–2024 (median age, 16 years; interquartile range [IQR], 14–17 years); the median prescribed daily dose was 600 mg (IQR, 400–800 mg; range, 200–2000 mg). Valproate was prescribed for treating epilepsy for 221 patients (90%), including 97 (44%) with drug-resistant epilepsy; 160 patients (65%) had neurodevelopmental disabilities. Teratogenicity was discussed with 32 patients (13%), less frequently with patients with a neurodevelopmental disability (9% vs. 20%; odds ratio [OR], 0.41; 95% confidence interval [95% CI], 0.19–0.88). Contraception was discussed with 69 patients (28%); the proportion was larger for patients with neurodevelopmental disabilities (34% vs. 16%; OR, 2.66; 95% CI, 1.37–5.14). Contraception was prescribed for 50 patients (20%); the proportion was larger for patients with neurodevelopmental disabilities (25% vs. 12%; OR, 2.50; 95% CI, 1.18–5.30). The national PBS-subsidised dispensing rate during 2023 was 621 per 100,000 girls and women aged 13–18 years; in Victoria it was 556 per 100,000 girls and women aged 13–18 years.</p> </section> <section> <h3> Conclusion</h3> <p>Despite the risk of teratogenicity, valproate was prescribed for a
目的:评估墨尔本皇家儿童医院育龄女性患者丙戊酸酯的处方频率,并评估与这些患者讨论丙戊酸酯致畸性和讨论或处方避孕的频率。研究设计:回顾性审核医院电子病历数据;药品福利计划(PBS)丙戊酸配药数据分析。背景,参与者:2022年5月29日至2024年5月29日期间在墨尔本皇家儿童医院接受丙戊酸处方的13至18岁女孩或妇女;2023日历年澳大利亚PBS丙戊酸盐分配数据。主要观察指标:服用丙戊酸钠的青少年女性患者的特点;丙戊酸相关致畸性的文献讨论,以及避孕处方的讨论;人口丙戊酸处方率澳大利亚和各州。结果:2022-2024年间,共有245例13-18岁女性患者使用丙戊酸钠(年龄中位数为16岁,四分位数间距[IQR]为14-17岁);中位处方日剂量为600毫克(IQR, 400-800毫克;范围,200-2000毫克)。221例(90%)患者使用丙戊酸钠治疗癫痫,其中97例(44%)为耐药癫痫;160例(65%)有神经发育障碍。32名患者(13%)讨论了致畸性,神经发育障碍患者较少讨论致畸性(9% vs. 20%;优势比[OR], 0.41; 95%可信区间[95% CI], 0.19-0.88)。69例患者(28%)讨论避孕;神经发育障碍患者的比例更大(34%对16%;OR, 2.66; 95% CI, 1.37-5.14)。50例(20%)患者开了避孕处方;神经发育障碍患者的比例更大(25%对12%;OR, 2.50; 95% CI, 1.18-5.30)。2023年,全国公共广播公司补贴的配药率为每10万名13-18岁的女孩和妇女621人;在维多利亚州,每10万名13-18岁的女孩和妇女中有556人死亡。结论:尽管丙戊酸有致畸风险,但在2022-2024年和2023年期间,皇家儿童医院为相当多的女性青少年开了丙戊酸处方。很少与患者讨论其致畸性,也没有频繁讨论或处方避孕。神经发育障碍患者更常讨论和处方避孕,但致畸性较少讨论。
{"title":"Valproate Prescribing for Female Adolescents and Management of the Associated Teratogenicity Risk, Royal Children's Hospital, Melbourne, 2022–2024: A Retrospective Audit of Medical Records Data","authors":"Briana Davis,&nbsp;Monica S. Cooper,&nbsp;Michael South,&nbsp;Jeremy L. Freeman,&nbsp;Emma Macdonald-Laurs","doi":"10.5694/mja2.70126","DOIUrl":"10.5694/mja2.70126","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To assess the frequency of valproate prescribing for female patients of childbearing age at the Royal Children's Hospital, Melbourne, and to assess the frequency of documented discussions with these patients about the teratogenicity of valproate and the discussions or prescribing of contraception.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Study Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Retrospective audit of hospital electronic medical records data; analysis of Pharmaceutical Benefits Scheme (PBS) valproate dispensing data.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting, Participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;13- to 18-year-old girls or women prescribed valproate at the Royal Children's Hospital, Melbourne during 29 May 2022–29 May 2024; PBS valproate dispensing data for Australia for the 2023 calendar year.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main Outcome Measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Characteristics of adolescent female patients prescribed valproate; documented discussions of valproate-related teratogenicity, and discussions or prescribing of contraception; population valproate prescribing rates for Australia and by state.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Valproate was prescribed for 245 female patients aged 13–18 years during 2022–2024 (median age, 16 years; interquartile range [IQR], 14–17 years); the median prescribed daily dose was 600 mg (IQR, 400–800 mg; range, 200–2000 mg). Valproate was prescribed for treating epilepsy for 221 patients (90%), including 97 (44%) with drug-resistant epilepsy; 160 patients (65%) had neurodevelopmental disabilities. Teratogenicity was discussed with 32 patients (13%), less frequently with patients with a neurodevelopmental disability (9% vs. 20%; odds ratio [OR], 0.41; 95% confidence interval [95% CI], 0.19–0.88). Contraception was discussed with 69 patients (28%); the proportion was larger for patients with neurodevelopmental disabilities (34% vs. 16%; OR, 2.66; 95% CI, 1.37–5.14). Contraception was prescribed for 50 patients (20%); the proportion was larger for patients with neurodevelopmental disabilities (25% vs. 12%; OR, 2.50; 95% CI, 1.18–5.30). The national PBS-subsidised dispensing rate during 2023 was 621 per 100,000 girls and women aged 13–18 years; in Victoria it was 556 per 100,000 girls and women aged 13–18 years.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Despite the risk of teratogenicity, valproate was prescribed for a","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.70126","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146010846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Total Pancreatectomy and Islet Auto Transplantation in South Australia: A Preliminary Evaluation of a 10-Year Experience 南澳大利亚全胰切除术和胰岛自体移植:10年经验的初步评价。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-19 DOI: 10.5694/mja2.70129
Gorjana Radisic, Colleen Etherton, Alice Rickard, Merle Weetra, Denghao Wu, Sanjeev Khurana, Bhanu Mariyappa, Jenny Harrington, Tom Loudovaris, Gordon Thomas, Henry C. C. Pleass, Alex Brown, Thomas W. Kay, Christopher J. Drogemuller, David J. Torpy, Richard Couper, John Chen, Patrick T. Coates

Hereditary pancreatitis causes severe early-onset pain and hospitalisation. In 15 Australian patients undergoing total pancreatectomy and islet auto transplantation (TPIAT), we observed a marked reduction in hospital admissions, inpatient days and emergency visits, complete analgesic cessation by 24 months and durable insulin independence in nearly half of the patients. These findings highlight TPIAT’s potential to improve quality of life and reduce healthcare burden. Our programme aims to build evidence to support public funding and ensure equitable access to this procedure.

遗传性胰腺炎引起严重的早发性疼痛和住院治疗。在15名接受全胰腺切除术和胰岛自体移植(TPIAT)的澳大利亚患者中,我们观察到住院次数、住院天数和急诊次数显著减少,近一半患者24个月完全停止止痛,并能持久胰岛素独立。这些发现强调了TPIAT在改善生活质量和减轻医疗负担方面的潜力。我们的项目旨在建立证据,以支持公共资助,并确保公平获得这一程序。
{"title":"Total Pancreatectomy and Islet Auto Transplantation in South Australia: A Preliminary Evaluation of a 10-Year Experience","authors":"Gorjana Radisic,&nbsp;Colleen Etherton,&nbsp;Alice Rickard,&nbsp;Merle Weetra,&nbsp;Denghao Wu,&nbsp;Sanjeev Khurana,&nbsp;Bhanu Mariyappa,&nbsp;Jenny Harrington,&nbsp;Tom Loudovaris,&nbsp;Gordon Thomas,&nbsp;Henry C. C. Pleass,&nbsp;Alex Brown,&nbsp;Thomas W. Kay,&nbsp;Christopher J. Drogemuller,&nbsp;David J. Torpy,&nbsp;Richard Couper,&nbsp;John Chen,&nbsp;Patrick T. Coates","doi":"10.5694/mja2.70129","DOIUrl":"10.5694/mja2.70129","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Hereditary pancreatitis causes severe early-onset pain and hospitalisation. In 15 Australian patients undergoing total pancreatectomy and islet auto transplantation (TPIAT), we observed a marked reduction in hospital admissions, inpatient days and emergency visits, complete analgesic cessation by 24 months and durable insulin independence in nearly half of the patients. These findings highlight TPIAT’s potential to improve quality of life and reduce healthcare burden. Our programme aims to build evidence to support public funding and ensure equitable access to this procedure.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146003631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adolescent Pregnancy Among Girls Known to Child Protection Services: An Australian Longitudinal Cohort Study Using Data Linkage 青少年怀孕的女孩知道儿童保护服务:澳大利亚纵向队列研究使用数据链接。
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-18 DOI: 10.5694/mja2.70130
Oliver Watkeys, Kimberlie Dean, Kristin R. Laurens, Stacy Tzoumakis, Vaughan J. Carr, Melissa J. Green

In a population cohort of 44,216 adolescent girls, about 73.5% of those who became pregnant were known to child protection services. Exposure to higher levels of child protection response was associated with increased cumulative incidence and an earlier age of pregnancy.

在44,216名少女的人口队列中,约73.5%的怀孕少女接受过儿童保护服务。暴露于较高水平的儿童保护反应与增加的累积发病率和较早的怀孕年龄有关。
{"title":"Adolescent Pregnancy Among Girls Known to Child Protection Services: An Australian Longitudinal Cohort Study Using Data Linkage","authors":"Oliver Watkeys,&nbsp;Kimberlie Dean,&nbsp;Kristin R. Laurens,&nbsp;Stacy Tzoumakis,&nbsp;Vaughan J. Carr,&nbsp;Melissa J. Green","doi":"10.5694/mja2.70130","DOIUrl":"10.5694/mja2.70130","url":null,"abstract":"<div>\u0000 \u0000 <p>In a population cohort of 44,216 adolescent girls, about 73.5% of those who became pregnant were known to child protection services. Exposure to higher levels of child protection response was associated with increased cumulative incidence and an earlier age of pregnancy.</p>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early Cessation of Acetylcysteine Treatment After Paracetamol Overdose (NACSTOP 2): A Non-Inferiority Randomised Controlled Trial 乙酰氨基酚过量后早期停止乙酰半胱氨酸治疗(NACSTOP 2):一项非劣效性随机对照试验
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-18 DOI: 10.5694/mja2.70114
Anselm Wong, Richard McNulty, Sarah E. Hodgson, Naren Gunja, Andis Graudins
<div> <section> <h3> Objectives</h3> <p>To determine whether ceasing acetylcysteine treatment for adults with acute paracetamol overdose after at least 12 h of the two-bag acetylcysteine regimen is non-inferior to providing the full 20-h two-bag regimen.</p> </section> <section> <h3> Study Design</h3> <p>Open label, non-inferiority randomised controlled trial.</p> </section> <section> <h3> Setting</h3> <p>Emergency departments of six Australian metropolitan hospitals (four in Melbourne, two in Sydney), 1 December 2019–31 July 2024.</p> </section> <section> <h3> Participants</h3> <p>Adults who required acetylcysteine treatment following single or staggered paracetamol ingestions whose serum alanine transaminase (ALT) level was below 40 IU/L on presentation, and whose ALT levels were below 40 IU/L and serum paracetamol concentrations below 20 mg/L after 12 h of acetylcysteine treatment.</p> </section> <section> <h3> Intervention</h3> <p><i>Control group</i> (standard care): two-bag intravenous acetylcysteine regimen (200 mg/kg over 4 h, followed by 100 mg/kg over 16 h). <i>Intervention group</i>: Acetylcysteine stopped at least 12 h after treatment initiation and the 20-h infusion period completed with intravenous compound sodium lactate.</p> </section> <section> <h3> Main Outcome Measures</h3> <p>Difference in ALT level between presentation and 20 h after acetylcysteine treatment initiation; non-inferiority was defined as the upper limit of the 95% confidence interval (CI) of the difference between median changes in ALT level for the intervention and control groups being less than 3 IU/L.</p> </section> <section> <h3> Results</h3> <p>Of 2830 people who presented with paracetamol overdose, 860 received acetylcysteine treatment; 186 people who met both the presentation and 12-h acetylcysteine treatment blood test inclusion criteria (median age, 17 years; interquartile range [IQR], 16–23 years; 162 women [87%]) were randomly assigned to the intervention (93 participants) and control groups (93 participants). Median acetylcysteine infusion time in the intervention group was 13 h (IQR, 13–13 h). The median change in ALT level between arrival and 20 h after starting intravenous acetylcysteine treatment was similar for the intervention (−1 IU/L; IQR, −4 to
目的:确定急性扑热息痛过量的成人在接受至少12小时的两袋乙酰半胱氨酸治疗方案后停止乙酰半胱氨酸治疗是否优于提供完整的20小时两袋方案。研究设计:开放标签、非劣效性随机对照试验。环境:2019年12月1日至2024年7月31日,澳大利亚六家大城市医院(墨尔本四家,悉尼两家)的急诊科。受试者:单次或交错服用扑热息痛后需要乙酰半胱氨酸治疗的成人,入院时血清丙氨酸转氨酶(ALT)水平低于40 IU/L,乙酰半胱氨酸治疗12小时后ALT水平低于40 IU/L,血清扑热息痛浓度低于20 mg/L。干预:对照组(标准护理):两袋静脉注射乙酰半胱氨酸方案(200 mg/kg超过4 h,随后100 mg/kg超过16 h)。干预组:乙酰半胱氨酸在治疗开始后至少12 h停止,复方乳酸钠静脉滴注20 h。主要观察指标:乙酰半胱氨酸治疗开始后20小时与入院时ALT水平的差异;非劣效性定义为干预组与对照组ALT水平中位变化差异的95%置信区间(CI)的上限小于3 IU/L。结果:2830例出现扑热息痛过量的患者中,860例接受了乙酰半胱氨酸治疗;186名符合首发和12小时乙酰半胱氨酸治疗血液检查纳入标准的患者(年龄中位数为17岁;四分位间距[IQR], 16-23岁;162名女性[87%])被随机分配到干预组(93名参与者)和对照组(93名参与者)。干预组乙酰半胱氨酸输注时间中位数为13 h (IQR, 13-13 h)。介入组(-1 IU/L; IQR, -4 ~ 1 IU/L)与对照组(0 IU/L; IQR, -2 ~ 2 IU/L)的ALT水平在开始静脉注射乙酰半胱氨酸治疗后20小时内的中位变化相似;中位变化差异(-1 IU/L; 95% CI, -2至1 IU/L)与非劣效性标准一致。无患者发生肝损伤或肝毒性。结论:乙酰半胱氨酸缩短治疗方案不逊于标准的20小时两袋治疗方案,适用于对乙酰氨基酚过量且肝衰竭风险低的患者。试验注册:ACTRN12619001549112(前瞻性)。
{"title":"Early Cessation of Acetylcysteine Treatment After Paracetamol Overdose (NACSTOP 2): A Non-Inferiority Randomised Controlled Trial","authors":"Anselm Wong,&nbsp;Richard McNulty,&nbsp;Sarah E. Hodgson,&nbsp;Naren Gunja,&nbsp;Andis Graudins","doi":"10.5694/mja2.70114","DOIUrl":"10.5694/mja2.70114","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To determine whether ceasing acetylcysteine treatment for adults with acute paracetamol overdose after at least 12 h of the two-bag acetylcysteine regimen is non-inferior to providing the full 20-h two-bag regimen.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Study Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Open label, non-inferiority randomised controlled trial.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Emergency departments of six Australian metropolitan hospitals (four in Melbourne, two in Sydney), 1 December 2019–31 July 2024.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Adults who required acetylcysteine treatment following single or staggered paracetamol ingestions whose serum alanine transaminase (ALT) level was below 40 IU/L on presentation, and whose ALT levels were below 40 IU/L and serum paracetamol concentrations below 20 mg/L after 12 h of acetylcysteine treatment.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Intervention&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;&lt;i&gt;Control group&lt;/i&gt; (standard care): two-bag intravenous acetylcysteine regimen (200 mg/kg over 4 h, followed by 100 mg/kg over 16 h). &lt;i&gt;Intervention group&lt;/i&gt;: Acetylcysteine stopped at least 12 h after treatment initiation and the 20-h infusion period completed with intravenous compound sodium lactate.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main Outcome Measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Difference in ALT level between presentation and 20 h after acetylcysteine treatment initiation; non-inferiority was defined as the upper limit of the 95% confidence interval (CI) of the difference between median changes in ALT level for the intervention and control groups being less than 3 IU/L.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Of 2830 people who presented with paracetamol overdose, 860 received acetylcysteine treatment; 186 people who met both the presentation and 12-h acetylcysteine treatment blood test inclusion criteria (median age, 17 years; interquartile range [IQR], 16–23 years; 162 women [87%]) were randomly assigned to the intervention (93 participants) and control groups (93 participants). Median acetylcysteine infusion time in the intervention group was 13 h (IQR, 13–13 h). The median change in ALT level between arrival and 20 h after starting intravenous acetylcysteine treatment was similar for the intervention (−1 IU/L; IQR, −4 to","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.70114","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A match made in health care: can ethics and governance better support impactful implementation research? 卫生保健领域的匹配:道德和治理能否更好地支持有影响力的实施研究?
IF 8.5 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2026-01-18 DOI: 10.5694/mja2.70109
Natalie Taylor, Zhicheng Li, Cathelijne van Kemenade, Jackie Curtis, Patrick Bolton
<p>Researchers are increasingly required to demonstrate the impact of their work. In contrast to traditional academic measures such as publications and citations, impact is determined by the successful translation and implementation of research findings into real-world settings that deliver direct benefits.<span><sup>1</sup></span> Translating research into policy and practice is a complex and often difficult process. A key challenge is effectively and sustainably implementing evidence-based interventions in the real world. Aside from controlled drug trials, making an impact in health care — such as driving behavioural or systemic change — and providing clear evidence of that impact, particularly demonstrating its sustainment, is regarded as the Holy Grail.<span><sup>2</sup></span> Applied research in health care often fails to demonstrate a meaningful contribution to health outcomes.<span><sup>3, 4</sup></span></p><p>When research fails to deliver impactful outcomes, research ethics and governance (REG) processes are often scrutinised for causing unnecessary delays and burdens (Box 1 shows the REG process in Australia for a multisite research application and the behind-the-scenes work). REG reviews are crucial in safeguarding the health and wellbeing of research participants and ensuring the compliance of the research activities with relevant institutional, jurisdictional and national standards. However, ineffective and bureaucratic regulation can lead to hyper-regulation, where the regulation, governance and management become excessively burdensome and disproportionate to the conceivable risks the research poses to participants.<span><sup>2, 5</sup></span> This is particularly challenging for implementation studies, which are at the nexus of clinical research and impact. This positioning introduces the challenge of defining the unique contribution to health outcomes within a research project and distinguishing its immediate role from the broader, long term effects the research may have on widespread change, which can take years or even decades to achieve. Although REG delays can compound these challenges, we argue that they also present opportunities to build meaningful relationships, enhance health systems research, and support lasting impact.</p><p>This article reflects on two implementation experiences in Australian hospital settings and presents an evidence-driven approach for categorising implementation barriers and identifying strategies to leverage REG processes as opportunities. Barriers encountered in these two case studies, directly and indirectly related to REG, were identified to highlight lessons learned from our successes and setbacks. To help overcome these barriers, we mapped them against two well-known implementation science frameworks: the Consolidated Framework for Implementation Research (CFIR) and the Expert Recommendations for Implementation Change (ERIC) implementation strategies (Box 2).<span><sup>6, 7</sup></span> Opera
越来越多的研究人员被要求证明他们工作的影响。与传统的学术衡量标准(如出版物和引用)相比,影响力取决于研究成果能否成功地转化和实施到能够带来直接利益的现实环境中将研究成果转化为政策和实践是一个复杂且往往困难的过程。一项关键挑战是在现实世界中有效和可持续地实施基于证据的干预措施。除了对照药物试验之外,对卫生保健产生影响——例如推动行为或系统改变——并提供这种影响的明确证据,特别是证明其可持续性,被视为圣杯。2卫生保健领域的应用研究往往不能证明对健康结果有意义的贡献。当研究未能产生有影响力的结果时,研究伦理和治理(REG)过程通常会受到审查,以避免造成不必要的延误和负担(框1显示了澳大利亚多地点研究应用的REG过程和幕后工作)。REG审查对于保障研究参与者的健康和福祉以及确保研究活动符合相关的机构、司法管辖区和国家标准至关重要。然而,无效的官僚监管可能导致过度监管,监管、治理和管理变得过于繁重,与研究给参与者带来的可能风险不成比例。这对实施研究尤其具有挑战性,因为实施研究是临床研究和影响的纽带。这种定位带来了一个挑战,即如何界定研究项目对健康成果的独特贡献,并将其直接作用与研究可能对广泛变化产生的更广泛的长期影响区分开来,而这种变化可能需要数年甚至数十年才能实现。尽管REG延迟可能会加剧这些挑战,但我们认为,它们也为建立有意义的关系、加强卫生系统研究和支持持久影响提供了机会。本文反映了澳大利亚医院设置的两个实施经验,并提出了一种循证驱动的方法,用于对实施障碍进行分类,并确定利用REG过程作为机会的战略。在这两个与REG直接或间接相关的案例研究中遇到的障碍被确定,以突出我们从成功和挫折中吸取的教训。为了帮助克服这些障碍,我们将它们与两个著名的实施科学框架进行了对比:实施研究综合框架(CFIR)和实施变革专家建议(ERIC)实施战略(方框2)。6,7在澳大利亚卫生保健和REG的背景下实施这些理论驱动的战略对于实现研究影响和促进持续变革至关重要。HaSP和S3L研究是两项大规模、多地点、非药物实施试验,旨在将卫生保健干预措施纳入澳大利亚医院网络的常规实践。8-10 HaSP侧重于改善Lynch综合征的检测,S3L研究旨在实施基于医院的戒烟干预措施。在REG过程中确定了三个关键障碍,包括由于冗长的官僚程序和获得相关研究治理批准的行政负担(障碍1),REG框架与实施性研究的性质不兼容(障碍2),以及过高估计临床试验分类下实施性研究的风险(障碍3)而导致的研究推出和总体时间表的延迟。其他障碍包括卫生服务利益相关者的角色和责任不明确(障碍4),缺乏中层管理人员(例如,病房经理,护理单位经理)的领导支持(障碍5),以及难以有效地向相关临床工作人员传达研究的基本原理和实施实践和研究的重要性(障碍6)。这些障碍虽然与REG过程没有直接关系,但它们共同阻碍了利益相关者的参与,并削弱了实施工作的总体势头。将这些障碍映射到cfr - eric战略中,突出了利用REG流程产生更大影响的机会。下面的讨论探讨了将有效的CFIR-ERIC实施策略纳入REG过程的方法,以克服当地环境中的障碍,在关键利益相关者之间建立共同的理解,并建立超越学术合作的关系。
{"title":"A match made in health care: can ethics and governance better support impactful implementation research?","authors":"Natalie Taylor,&nbsp;Zhicheng Li,&nbsp;Cathelijne van Kemenade,&nbsp;Jackie Curtis,&nbsp;Patrick Bolton","doi":"10.5694/mja2.70109","DOIUrl":"10.5694/mja2.70109","url":null,"abstract":"&lt;p&gt;Researchers are increasingly required to demonstrate the impact of their work. In contrast to traditional academic measures such as publications and citations, impact is determined by the successful translation and implementation of research findings into real-world settings that deliver direct benefits.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Translating research into policy and practice is a complex and often difficult process. A key challenge is effectively and sustainably implementing evidence-based interventions in the real world. Aside from controlled drug trials, making an impact in health care — such as driving behavioural or systemic change — and providing clear evidence of that impact, particularly demonstrating its sustainment, is regarded as the Holy Grail.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Applied research in health care often fails to demonstrate a meaningful contribution to health outcomes.&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;When research fails to deliver impactful outcomes, research ethics and governance (REG) processes are often scrutinised for causing unnecessary delays and burdens (Box 1 shows the REG process in Australia for a multisite research application and the behind-the-scenes work). REG reviews are crucial in safeguarding the health and wellbeing of research participants and ensuring the compliance of the research activities with relevant institutional, jurisdictional and national standards. However, ineffective and bureaucratic regulation can lead to hyper-regulation, where the regulation, governance and management become excessively burdensome and disproportionate to the conceivable risks the research poses to participants.&lt;span&gt;&lt;sup&gt;2, 5&lt;/sup&gt;&lt;/span&gt; This is particularly challenging for implementation studies, which are at the nexus of clinical research and impact. This positioning introduces the challenge of defining the unique contribution to health outcomes within a research project and distinguishing its immediate role from the broader, long term effects the research may have on widespread change, which can take years or even decades to achieve. Although REG delays can compound these challenges, we argue that they also present opportunities to build meaningful relationships, enhance health systems research, and support lasting impact.&lt;/p&gt;&lt;p&gt;This article reflects on two implementation experiences in Australian hospital settings and presents an evidence-driven approach for categorising implementation barriers and identifying strategies to leverage REG processes as opportunities. Barriers encountered in these two case studies, directly and indirectly related to REG, were identified to highlight lessons learned from our successes and setbacks. To help overcome these barriers, we mapped them against two well-known implementation science frameworks: the Consolidated Framework for Implementation Research (CFIR) and the Expert Recommendations for Implementation Change (ERIC) implementation strategies (Box 2).&lt;span&gt;&lt;sup&gt;6, 7&lt;/sup&gt;&lt;/span&gt; Opera","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"224 1","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12813301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical Journal of Australia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1